To conclude, LPS-Nb36 has a stronger antigen-binding ability than Nb36 and can more efficiently block the CTLA-4 signal pathway of CTLs activated by the DC/tumor fusion vaccine. The gene discussed is CTLA4; the disease is neoplasm.